Indeed, palbociclib is not sufficient to activate HDAC5-dependent RB inhibitory activity in HDAC5 KD cells, but concurrent treatment with NEO3724, a dual BET-CBP/p300 inhibitor, restores sensitivity to palbociclib in cancer cells and xenografts[173]. This evidence concerns the gene HDAC5 and cancer.